Anesthetic Techniques and Cancer Outcomes

Research over the past decade has uncovered that the choice and mode of anaesthesia administered during cancer surgery may influence long-term oncological outcomes. Beyond providing analgesia and unconsciousness, anaesthetic agents and techniques modulate the patient’s stress response, innate and adaptive immunity, and even cancer cell signalling. Inhalational agents can suppress natural killer cell activity and upregulate hypoxia-inducible pathways, whereas intravenous hypnotics such as propofol often exhibit anti-inflammatory and antioxidative properties. Regional and local anaesthesia attenuate neuroendocrine stress, preserve perioperative immune function and may reduce opioid requirements, potentially limiting the perioperative window during which residual tumour cells can proliferate or seed new metastases. Preclinical studies have also demonstrated direct cytotoxic or anti-stemness effects of certain local anaesthetics on tumour cells. Taken together, this body of evidence suggests that strategic selection of anaesthetic regimens—balancing intravenous, inhalational, regional and local approaches—could become an integral part of multimodal cancer-care pathways, optimising both surgical safety and long-term survival.

Research from Nature Portfolio

A large retrospective cohort study of patients undergoing oesophageal cancer resection compared volatile inhalational maintenance with total intravenous anaesthesia (propofol-based), using propensity-score matching to adjust for baseline characteristics. Intravenous anaesthesia was associated with significantly better overall and recurrence-free survival over several years of follow-up. The analysis controlled for tumour stage, adjuvant therapy and comorbidities, suggesting that choice of hypnotic agent during major cancer surgery may independently affect long-term outcomes. These findings have prompted calls for prospective trials to confirm causality and to inform guidelines on anaesthetic selection in onco-surgery.

Anesthetic Techniques and Cancer Outcomes publication trend

The graph below shows the total number of articles in anesthetic techniques and cancer outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Volatile anaesthetic: A gaseous or vapour-administered agent inducing unconsciousness, often through inhalation.

Total intravenous anaesthesia (TIVA): Maintenance of anaesthesia exclusively via intravenous agents, most commonly propofol.

Locoregional anaesthesia: Techniques that block nerve conduction in a defined region (e.g. epidural or peripheral nerve block), reducing systemic drug requirements.

Recurrence-free survival: Time after treatment during which a patient shows no signs of cancer returning.

Natural killer (NK) cells: Innate immune lymphocytes specialised in recognising and destroying tumour or virally infected cells without prior sensitisation.

References

1. Long-lasting postoperative analgesia with local anesthetic-loaded hydrogels prevent tumor recurrence via enhancing CD8+T cell infiltration. Journal of Nanobiotechnology (2023).
2. Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer. Journal of Experimental & Clinical Cancer Research (2024).
3. Impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study, comparing propofol and sevoflurane. EClinicalMedicine (2023).
4. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. Journal of Translational Medicine (2018).
5. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study. Scientific Reports (2017).